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Abstract
Regulatory T cells (Treg) that express the transcription factor Foxp3 are enriched within a broad range of murine
and human solid tumors. The ontogeny of these Foxp3 Tregs - selective accumulation or proliferation of natural
thymus-derived Treg (nTreg) or induced Treg (iTreg) converted in the periphery from naïve T cells - is not known.
We used several strains of mice in which Foxp3 and EGFP are coordinately expressed to address this issue. We
confirmed that Foxp3-positive CD4 T cells are enriched among tumor-infiltrating lymphocytes (TIL) and splenocytes
(SPL) in B16 murine melanoma-bearing C57BL/6 Foxp3
EGFP mice. OT-II Foxp3
EGFP mice are essentially devoid of
nTreg, having transgenic CD4 T cells that recognize a class II-restricted epitope derived from ovalbumin; Foxp3
expression could not be detected in TIL or SPL in these mice when implanted with ovalbumin-transfected B16
tumor (B16-OVA). Likewise, TIL isolated from B16 tumors implanted in Pmel-1 Foxp3
EGFP mice, whose CD8 T cells
recognize a class I-restricted gp100 epitope, were not induced to express Foxp3. All of these T cell populations -
wild-type CD4, pmel CD8 and OTII CD4 - could be induced in vitro to express Foxp3 by engagement of their T cell
receptor (TCR) and exposure to transforming growth factor b (TGFb). B16 melanoma produces TGFb and both
pmel CD8 and OTII CD4 express TCR that should be engaged within B16 and B16-OVA respectively. Thus, CD8 and
CD4 transgenic T cells in these animal models failed to undergo peripheral induction of Foxp3 in a tumor
microenvironment.
Background
Treg play an essential role in maintaining immunologi-
cal self-tolerance [1]. Approximately 10% of CD4 T cells
express the transcription factor FoxP3 (forhead box P3
transcription factor); humans and mice with inactivating
Foxp3 mutations have autoimmune diseases [2-4]. Treg
dominantly suppress immune responses through direct
contact with dendritic cells, effector T cells and possibly
through secretion of immunosuppressive cytokines [5,6].
Fewer than 1% of CD8 T cells express Foxp3, and the
biology of this very small population of naturally occur-
ring, thymus-derived T cell have not been well studied.
However, this transcription factor can be induced in
both CD4 and CD8 T cells through engagement of their
T cell receptors (TCR) and exposure to transforming
growth factor beta (TGFb) [7-10]. These so called
“induced” Treg (iTreg), both CD4 and CD8, can acquire
dominant suppressor phenotype in a variety of experi-
mental models [11-13].
Many studies have shown that the number of Treg
are significantly increased in the peripheral blood,
bone marrow, tumor draining lymph nodes, and TIL
of mice and humans bearing many types of hematolo-
gic and solid malignancies including breast [14], color-
ectal [15], esophageal [16], gastric [17], hepatocellular
[18], lung [19], melanoma [20], ovarian [21], and pan-
creatic cancers [14]. It has been hypothesized that
these Treg may be involved with promoting tumor
progression, as they are even more enriched in
advanced tumors [22]. The number of Foxp3 Treg
within human tumors has also been correlated with a
poorer prognosis. Patients with ovarian or gastric can-
cer and lower numbers of Treg TILs had improved
disease-specific survival [23]; those with head and neck
cancer also experienced better locoregional control
[24]. Treg isolated from human ovarian cancers were
able to inhibit Her-2 specific CD8+ effector responses,
as measured by proliferation, cytotoxicity, and IL2 and
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support the view that Foxp3 Treg may dominantly
suppress antitumor immune responses. The ontogeny
of the enriched Treg population found within tumors,
generally CD4, is not fully defined. A selective tumor-
driven accumulation or proliferation of thymus-derived
natural (n)Treg is a possibility. Alternatively, naïve
Foxp3 T cells could be induced to express this regula-
tory transcription factor through tumor-derived signals
yielding induced (i)Treg. These signals would include
engagement of TCR and exposure to TGFb elaborated
by tumors or tumor-associated stroma. We sought to
address this question by generating CD8 (Pmel-1) and
CD4 (OTII) TCR transgenic mice in which Foxp3
expression could be detected by EGFP expression
(Foxp3
EGFP). These naïve Pmel-1 CD8 and OTII CD4
populations have very low to absent Foxp3 expression
but could be induced in T cells in vitro with a combi-
nation of T cell receptor (TCR) engagement and TGFb
signaling. We reasoned that both of these TCR trans-
genic cell populations, entering B16 or ovalbumin-
transfected B16 (B16-OVA) subcutaneous tumors
respectively, would be exposed to a comparable set of
Foxp3 induction signals. CD4/Foxp3
EGFP cells are
enriched in B16 tumors and spleen when tumors are
propagated in wild-type C57BL/6 Foxp3
EGFP mice.
However, in neither TCR transgenic mouse did we
find evidence of Foxp3 induction among tumor-infil-
trating lymphocytes (TIL), splenocytes (SPL) nor
lymph nodes (LN). These findings argue indirectly in
favor of a preferential accumulation of nTreg in
experimental tumors.
Materials and methods
Mice
Mice were bred and kept under defined-flora patho-
gen-free conditions at the American Association of
Laboratory Animal Care-approved Animal Facility of
the Division of Experimental Radiation Oncology,
University of California,L o sA n g e l e s .M i c ew e r e
handled in accordance with the University of Califor-
nia animal care policy. Foxp3
EGFP mice were derived
as previously described [26] and backcrossed for 12
generations on the C57BL/6 background. The follow-
ing mouse strains, all on C57BL/6 background, were
obtained from the Jackson Laboratory: Recombinase
activating gene 1 (RAG1)-deficient mice, Pmel-1 TCR
transgenic mice that recognize the MHC class I (H-2
D
b)-restricted epitope of gp100 (25-33) presented on
the surface of B16 melanoma, and OTII TCR trans-
genic mice whose transgenic receptor recognizes oval-
bumin 323-339 in the context of I-A
b.P m e l -
Foxp3
EGFP mice, and OTII-RAG1KO-Foxp3
EGFP mice
(OTII-Foxp3
EGFP mice) were derived by crossing the
respective mice.
Tumors cell lines and adoptive therapy
The murine melanoma cell line B16 was obtained from
the American Type Culture Collection and maintained
in Dulbecco’s modified Eagle’s medium plus 10% FBS,
penicillin (100 U/ml), streptomycin (100 μg/ml),
Amphotericin B (0.25 μg/ml). B16-OVA (expressing the
gene for ovalbumin peptide), a kind gift from Protul
Shrikant, was cultured in RPMI (Mediatech Cell Gro)
1640 medium as described above, plus G418 (Invitrogen,
400 μg/ml). IL-2 was a kind gift from Chiron Corpora-
tion (Novartis).
Adoptive cell therapy
Adoptive cell therapy, mouse irradiation, bone marrow
transplantation and systemic IL-2 administration were
conducted as previously described [27]. Specific details
with respect to cell numbers may be found in the foot-
note to Table 1.
Flow cytometry
A single cell suspension was prepared from spleens and
lymph nodes in PBS by filtering through a 0.7 μmm e s h
cell strainer. A total of 10
6 splenocytes were then
labeled with mAb mixtures (BD Pharmingen) to
CD3
PerCP(5 μg/ml), CD8a
PE (5 μg/ml), and/or CD4
APC
(5 μg/ml). Non-specific antibody binding was blocked
on cells with Fc-blocking solution (5 μg/ml) for 10 min-
utes. Cells were then labeled for 30 min on ice in the
dark, washed, fixed (if analysis was to take place on fol-
lowing day), and analyzed. Stained cells were collected
and analyzed on a FACSCalibur machine, using Cell-
Quest software, and numbers of T cells populations and
% EGFP-positive cells were measured. To isolate tumor-
inflitrating lymphocytes (TIL) ,as i n g l ec e l ls u s p e n s i o n
was prepared in the following manner: tumors were
minced with sterile surgical blades in 5 mL PBS in a
petri dish, washed twice with PBS, enzymatically
digested in 0.1% Dispase II solution (Roche) for 40 min
at room temperature with gentle mixing, and re-sus-
pended in PBS. RBC were lysed with 1× PharmLyse (BD
Pharmingen), and cells were washed, re-suspended in
RPMI 1640 medium with 10% FBS and 1% PSF, and
counted. The numbers of TIL isolated varied widely and
correlated to a large degree with the size of the tumor.
As few as several thousand to greater than a half million
TIL could be isolated from each tumor. The entire lym-
phocyte population from each tumor was analyzed by
flow cytometry. Additional files 1 and 2 show gating
strategies for Foxp3
EGFP T reg isolated from mice or
generated in vitro, respectively.
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Freshly explanted B16 tumor cells, B16 cultured cells, or
B16-OVA cultured cells were plated in one well of a
six-well plate in described media on day 0. On day 2,
cells were washed and resuspended in 2 mL serum-free
and antibiotic-free DMEM or RPMI. On day 3, when
the cells were 100% confluent, supernatants were col-
lected. Supernatant TGFb concentrations were measured
using ELISA (Mouse/Rat/Porcine/Canine TGFb 1 Quan-
tikine ELISA Kit; R&D Systems) according to the manu-
facturer’s recommendation.
Statistical analysis
Statistical analysis and P-value determinations were
done by two-tailed Welch’s T-test for determination of
the significance of differences between the groups of
continuous variables. P < 0.05 was considered to be sta-
tistically significant. Graphs were constructed using
GraphPad Prism 4.0 software and statistical functions
were analyzed using Microsoft Excel.
Results
Foxp3-positive CD4 T cells are enriched in tumor-
infiltrating lymphocytes
Many groups have reported high percentages of Foxp3-
positive lymphocytes infiltrating both murine and
human tumors and have postulated that these Treg may
dominantly suppress an antitumor immune response
[25,28]. We confirmed this in C57BL/6 Foxp3
EGFP mice
in which Foxp3/Treg are identified by EGFP expression;
in these mice an IRES-linked EGFP is bicistronically co-
expressed with Foxp3 under control of the endogenous
Foxp3 promoter/enhancer.[29] B16 melanoma was pro-
pagated subcutaneously in these mice. At various tumor
volumes, tumor-infiltrating lymphocytes (TIL), spleno-
cytes (SPL), and lymph node (LN) cells were isolated
and CD8 and CD4 T cells analyzed by flow cytometry
for percentage expression of Foxp3 (EGFP). A signifi-
cantly higher percentage of CD4 TIL expressed Foxp3
compared with CD4 SPL (30% vs. 13%, p = 0.016,
Welch’s T-test for unequal variances). Treg were
enriched in spleens but not lymph nodes of tumor-bear-
ing animals compared with healthy controls (p = 0.003).
A very low percentage (<1%) of CD8 T cells express
Foxp3; this was unchanged in tumor-bearing mice.
T cell receptor transgenic CD8 and CD4 T cells are not
induced to express Foxp3 in tumor-bearing mice
The ontogeny of these enriched Foxp3-positive cells in
tumor-bearing hosts is still a matter of controversy: do
they represent thymus-derived natural Treg (nTreg) or
induced Treg (iTreg) derived from naïve T cells in
which Foxp3 expression is induced through some
tumor-dependent mechanism? To address this question,
we crossed C57BL/6 Foxp3
EGFP mice (on a RAG-1 -/-
background) with Pmel mice (on a wild-type back-
ground) and with OTII mice (on a RAG-1 -/- back-
ground). Mice yielded from the former cross (Pmel/
Foxp3
EGFP) express the pmel TCR on approximately
70% of their CD8 T cells. This TCR recognizes the
MHC class I (H-2D
b)-restricted epitope of gp100 (25-
33) presented on the surface of B16 melanoma; adop-
tively transferred pmel CD8 T cells can mediate regres-
sion of B16 in vivo. Generally fewer than 0.3% of Pmel
CD8 express Foxp3
EGFP. The biology CD4 T cell popu-
lation in these Pmel mice have not been studied; we
noted an increased percent expression of Foxp3 in CD4s
from both control and tumor-bearing mice, and to a
comparable degree. Other investigators (R. Prins) have
reported that CD4s from these mice also express the
Pmel TCR, but we did not investigate this further as
this study was focused on CD8 Pmel population. Mice
yielded from the latter cross (OTII/Foxp3
EGFP)a r e
devoid of CD8s and express a TCR on their CD4 T cells
that recognize a class II (H-2IA
6)-restricted epitope
Table 1 Spleen cells were isolated and cultured for 72 hours under the indicated conditions with the following
concentrations: IL-2 (100 u/ml), TGFb (10 ng/ml) and aCD3/aCD28 (1 μg/ml immobilized, 10 μg/ml soluble,
respectively)
Culture Conditions C57BL/6 Foxp3
EGFP
CD8
C57BL/6 Foxp3
EGFP
CD4
Pmel Foxp3
EGFP
CD8
Pmel
Foxp3
EGFP
CD4
OTII Foxp3EGFP
CD4
Media Only 0.9 +/- 0.6 2.1 +/- 1.3 2.2 +/- 0.1 9.6 +/- 5.9 0.8 +/- 0.1
IL-2 1.9 +/- 0.5 8.2 +/- 1.8 2.9 +/- 0.1 11.7 +/- 1.3 0.6 +/- 0.3
TGF- b 1.8 +/- 0.1 4.2 +/- 1.1 4.8 +/- 0.8 13.2 +/- 1.6 0 +/- 0.6
IL-2/TGF-b 2.0 +/- 1.3 20.4 +/- 1.4 1.4 +/- 0.8 20.7 +/- 3.4 0.8 +/- 0.5
aCD3/aCD28 0.9 +/- 1.8 3.1 +/- 0.2 2.3 +/- 0.3 17.2 +/- 1.7 3.0 +/- 0.1
aCD3/aCD28/IL-2 1.3 +/- 1.6 4.6 +/- 0.7 21.3 +/- 0.8 13.8 +/- 0.5 3.0 +/- 0.2
aCD3/aCD28/TGF-b 18.8 +/- 3.0 18.8 +/- 1.0 27.3 +/- 1.8 30.7 +/- 2.8 7.7 +/- 2.4
aCD3/aCD28/IL-2/TGFb 25.1 +/- 0.4 34.4 +/- 1.1 27.9 +/- 0.2 46.2 +/- 1.1 8.4 +/- 0.4
Cells were then sorted for CD8, CD4, and EGFP expression. Results are a mean of triplicates +/- S.D. These experiments were repeated at least 3 times with
comparable results.
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lack nTreg because OVA is not presented in the
thymus.
We propagated B16 and B16-OVA tumors in Pmel
Foxp3
EGFP and OTII Foxp3
EGFP mice, respectively. At
various tumor volumes, SPL, LN, and TIL were analyzed
for percent expression of Foxp3
EGFP in CD8 and CD4 T
cells. In Pmel/Foxp3
EGFP mice, we did not observe any
significant enrichment of CD8/Foxp3
EGFP positive cells
in these sites. Higher percentages of CD4/Foxp3 positive
cells were found in spleens and LN from nontumor-
bearing Pmel/Foxp3
EGFP mice compared to C57BL/6
Foxp3
EGFP mice (overall average 25% compared with
12%), but there was no additional Foxp3 enrichment
among CD4 TIL in tumor-bearing animals. In OTII/
Foxp3
EGFP mice, at most 0.2% of CD4 T cells retrieved
from B16-OVA tumor-bearing mice express Foxp3
EGFP.
Signaling requirements for Foxp3 induction in TCR
transgenic CD8 and CD4 T cells
These in vivo studies suggested that naïve Foxp3-nega-
tive CD8 and CD4 T cells could not be induced to
express Foxp3 after they have infiltrated and been
exposed to signals within the tumor microenvironment.
We confirmed that naïve Foxp3-negative CD4 and CD8
populations, both TCR-transgenic and nontransgenic,
were capable of being induced to express Foxp3
EGFP by
in vitro TCR engagement (aCD3 and aCD28) and expo-
sure to TGFb (Table 1). Cells cultured from freshly
explanted B16 tumors produced TGFb at levels ranging
from 3.5 to 4.0 ng/mL, three-fold higher than that pro-
duced by B16 cells maintained in culture (data not
shown), possibly because of contamination by tumor-
associated macrophages. This nanogram concentration
level of TGFb in the tumor microenvironment should
be adequate to induce Foxp3.
IL-2 plays an important role in Treg maintenance and
iTreg development (ref). To overcome any deficiency in
this regard, we administered systemic IL-2 (50-250 ×
10
5 IU/mouse/day ×3 days prior to sacrifice) to several
tumor-bearing animals of all three strains (shown as
closed squares in Figures 1, 2 &3) but the proportions
of Foxp3
EGFP cells in these mice were unchanged.
Adoptive transfer of Foxp3-negative CD4 and CD8 T cells
into tumor-bearing mice
We finally asked if Foxp3-negative CD4 or CD8 T cells,
adoptively transferred into tumor-bearing mice, could
be induced to express this transcription factor. Popula-
tions of Foxp3
EGFP-positive and-negative CD4 and CD8
T cells were adoptively transferred to C57BL/6 wild type
B16-OVA-bearing mice. Adoptively transferred cell
populations included: C57BL / 6C D 4 ,n T r e g ,a n di T r e g ;
OTII CD4 and iTreg; and Pmel CD8s (see footnote to
Table 2 for details). Prior to adoptive transfer, mice
underwent a myeloablative regimen (900cGy) to allow
repopulation of lymphoid organs by the administered T
cells. Mice were supported with bone marrow from
C57BL/6 on a CD45.1 background to allow unequivocal
identification of adoptively transferred CD45.2 cells. All
mice received systemic IL-2 (50,000 units intraperito-
neal) on days 1, 2, and 3 after adoptive transfer. At
intervals after adoptive therapy, splenocytes were iso-
lated from recipient mice and analyzed for CD45.2, CD8
or CD4, and EGFP expression.
Shown in Table 2 is the percent Foxp3
EGFP expression
for administered CD4 and CD8 T cells retrieved from
spleen and TIL. Administered nTreg and iTreg could be
recovered from the spleens of recipient mice. However,
we did not detect induction of Foxp3 in repopulated
spleens of any of the other administered populations of
Foxp3
EGFP-negative CD4 or CD8 T cells. Insufficient
numbers of TIL were recovered in most groups to pro-
vide a reliable analysis.
Discussion
We hypothesized that naïve T cells entering the tumor
microenvironment would be exposed to the signals and
factors needed for induction of Foxp3 and the acquisi-
tion of a regulatory phenotype. Some of these signals
have been defined in vitro and include TCR engagement
and exposure to TGFb. We used TCR transgenic mice -
one devoid of CD4 nTreg and the other with < 1%
Foxp3 CD8s - whose tumor-infiltrating T cells and per-
haps those in lymphoid organs of tumor-bearing mice
would be engaged by cognate antigen, as well as being
exposed to tumor-produced TGFb.W ed e m o n s t r a t e d
that naïve Foxp3-negative CD4 and CD8 populations,
both transgenic and nontransgenic, could be induced to
express Foxp3 in vitro by aCD3/aCD28 and TGFb
treatment (see Table 1). These in vitro findings confirm
that Foxp3 expression can be induced in both T cells
subtypes, and to comparable degrees, using similar sets
of signals. We confirmed a significant enrichment of
Foxp3-positive CD4 TIL and splenocytes in wild-type,
B16 tumor-bearing C57BL/6 Foxp3
EGFP mice. However,
neither CD8s in these mice, nor TCR transgenic T cells
in either Foxp3
EGFP cross, seemed to have encountered
the necessary intratumoral signals to induce Foxp3
expression. Administration of systemic IL-2, which we
have shown in vitro to act in concert, but not alone,
with TGFb to induce Foxp3, did not support induction
of iTreg in these transgenic mice. These findings indir-
ectly support the view that natural, thymus-derived Treg
preferentially accumulate, or proliferate, in the tumor
microenvironment.
Two subsets of Tregs are recognized - adaptive or
induced (iTreg) and natural (nTreg) - which together are
responsible for maintaining tolerance to self-antigen and
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responses involved in allergic diseases through the sup-
pression of auto-reactive T cells [30,31]. Both require
TGF-b and IL-2 for maintenance; express similar phenoty-
pic markers such as CTLA4, GITR, CD25, and CCR4; and
require the expression of Foxp3 to carry out a contact-
dependent mechanism of action [32]. Where these two
developmentally distinct populations differ is in their anti-
gen specificities, strength of TCR stimulation and co-sti-
mulatory signals required for their generation, and their
stability of suppressive action. nTreg are generated in the
thymus in a CD28-dependent manner, constitutively
express CD25, express TCRs specific for self-antigen,
demonstrate a more stable expression of Foxp3, and exert
suppressive function [30-32]. Conversely, iTregs are gener-
ated in the peripheral lymphoid organs through the de
novo conversion of CD4
+CD25
-Foxp3
- T cells in a TGF-
b- and IL-2-dependent-manner, have TCRs specific for
foreign antigens presented by professional antigen-pre-
senting cells, require weaker TCR stimulation (CD28 sti-
mulation not required), and demonstrate a less stable
expression of Foxp3 [30-34].
Figure 1 Expression of Foxp3
EGFP in T cells from tumor-bearing and control mice. Splenocytes (SPL), lymph node lymphocytes (LN), and
tumor-infiltrating lymphocytes (TIL) were isolated from control and B16 tumor-bearing C57BL/6 Foxp3
EGFP mice and analyzed by flow cytometry
for Foxp3
EGFP expression in CD8 and CD4 lymphocytes. B16 (boxes) or B16-OVA (open triangles) tumors were allowed to grow to 7-10 mm in
diameter at which point they either did (closed boxes) or did not receive daily intraperitoneal injections of 50,000 units IL-2 for three days prior
to analysis on the following day. Foxp3
EGFP expression in CD8 T cells from control and tumor-bearing mice were at equivalently low
percentages. The percent of CD4 cells that expressed Foxp3
EGFP in SPL (p = 0.002) and TIL (p = 0.001) was significantly elevated in tumor-
bearing mice compared with non-tumor-bearing controls. Statistical analysis and P-value determinations were done by two-tailed Welch’s T-test
for determination of the significance of differences between the groups of continuous variables. P < 0.05 was considered to be statistically
significant. Graphs were constructed using GraphPad Prism 4.0 software and statistical functions were analyzed using Micorsoft Excel.
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tumors include: preferential accumulation of nTreg, pro-
liferation of nTreg within tumors, or peripheral conver-
sion of naïve T cells to iTreg. Each mechanism is
dependent upon tumor-derived signals (chemokines,
cytokines, TCR engagement). One hypothesis is that
resident nTreg proliferate in the tumor microenviron-
ment [35]; another is that nTregs may weakly perceive
tumor related signals and be selectively recruited where
they may exert their suppressive function [25]. Treg can
migrate more efficiently into major non-lymphoid tissue
sites, such as tumors, due to their up-regulation of non-
lymphoid tissue-specific homing receptors [36]. In
human ovarian carcinoma, tumor cells and tumor-asso-
ciated macrophages were shown to produce a Treg-spe-
cific chemokine CCL22, which resulted in the specific
recruitment of Treg to the tumor microenvironment via
their CCR4 receptor [25]. Interestingly, the CCR4
receptor is expressed at higher levels in Treg than in
effector T cells in leukemia studies, suggesting its up-
regulation may be Treg-specific [37]. In this same ovar-
ian cancer model, IL-2 treatment was shown to up-regu-
l a t eC C R 4a sw e l la sC X C R 4 ,w h i c hf u r t h e re n h a n c e d
the ability of Treg to migrate to the tumor microenvir-
onment based on its elevated levels of the Treg ligands
CCL22 and CXCL12 [38,39]. Similar results were seen
in a gastric cancer model, in which elevated levels of
CCL17 and CCL26 in the tumor microenvironment
demonstrated a positive correlation with the frequency
of Foxp3 Treg, which can bind both these ligands with
its CCR4 receptor [40]. Furthermore, Treg had a higher
affinity for CCL17 and CCL22 than effector T cells in
vitro as determined by a migration assay.
Expression of the regulatory cytokine TGFb is abun-
dant in many tumors, particularly in advanced stages.
TGFb can promote proliferation of Treg in vivo; the
Figure 2 Expression of Foxp3
EGFP in Pmel-1 transgenic mice. The relative percentages of Foxp3
EGFP expression were comparable in
splenocytes (SPL), lymph node lymphocytes (LN), and tumor-infiltrating lymphocytes (TILs) from control or B16-tumor-bearing Pmel Foxp3
EGFP
mice. B16 tumors were allowed to grow to 7-10 mm in diameter at which point they either did (closed boxes) or did not (open boxes) receive
daily intraperitoneal injections of 250,000 units IL-2 for three days prior to analysis on the following day.
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and in vitro [41]. A number of additional chemokines
and cytokines are implicated in Treg proliferation or
induction, including IFNg, IL-6, IL-23, IL-21, Cox2, and
indolamine 2,3 dioxygenase [22,23,42-45]. Convincing in
vivo evidence that iTreg develop from conventional
CD4
+CD25
- T cells was shown a non-obese diabetic
(NOD) model, which normally exhibits extensive auto-
immune manifestations around 12-16 weeks of age.
When CD28
-/- NOD mice were treated with aCD3,
which has been shown to increase CD4
+CD25
+ Tc e l l s
and result in long-term remission of disease in regular
NOD, CD4
+CD25
+ T cells were generated de novo and
shown to be suppressive in vitro [46]. Neutralizing anti-
TGF-b given to these CD28
-/- NOD mice alongside
aCD3 prevented the aforementioned disease remission,
demonstrating the role of TGF-b in the generation of
iTreg and further supporting previous in vitro results.
Linehan [47,48] demonstrated that naïve CD4 T cells
were converted into Foxp3-positive Treg when adminis-
tered to Rag1-/- mice bearing TGFb-producing (Pan 02)
tumors. This conversion could be inhibited by TGFb
neutralizing antibody, was abrogated if naïve T cells
were obtained from mice whose T cells were insensitive
to TGFb signaling, and did not occur in mice bearing
tumors that did not produce TGFb (ESO 2). The high
levels of TGFb expression by this murine pancreatic
tumor cell line, and the longer interval (seven weeks) of
in vivo co-residence of naïve CD4 T cells and tumor,
may explain their clearcut but different findings.
Conclusion
In summary, we generated two TCR transgenic mouse
strains in which the de novo generation of iTreg could
be unequivocally demonstrated in vitro, and in which
putative signals for Foxp3 induction were present in the
Figure 3 Expression of Foxp3
EGFP in OTII transgenic mice. The relative percentages of Foxp3
EGFP expression were comparable in splenocytes
(SPL), lymph node lymphocytes (LN), and tumor-infiltrating lymphocytes (TIL) from control or B16-OVA-tumor-bearing OTII Foxp3
EGFP mice. B16-
OVA tumors were allowed to grow to 7-10 mm in diameter at which point they either did (closed square) or did not (open triangle) receive
daily intraperitoneal injections of IL-2 for three days prior to analysis on the following day. In this cohort, mice did not all receive the same dose
of IL2: the non-tumor bearing mouse received 250,000 units IL-2 per injection while mice in the tumor-bearing group received either 100 (one
mouse), 250 (three mice), or 500 (one mouse) thousand units per injection.
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anoma in wild-type mice resulted in the enrichment of
CD4 Foxp3 Treg in TIL and spleen; this tumor did not
induce an enrichment of either CD4 or CD8 Foxp3 in
these two transgenic mouse strains.
Additional material
Additional file 1: Gating Strategies for Treg populations isolated
from mice. This file shows representative examples of gating for CD8
and CD4 Foxp3
EGFP cells from the spleens and tumors from different
transgenic mice. These mice have been well described in previous
publications where gating dot plates have been illustrated (see ref #26
which describes the generation of these mice by our coauthor T.
Chatila). The numbers of infiltrating transgenic T cells varies with the size
of the tumor and time after infusion. See figures 1, 2, 3, Table 2.
Additional file 2: Gating Strategies for Treg populations generated
in vitro. This file shows representative examples of gating for CD8 and
CD4 Foxp3
EGFP cells generated in culture by different activated cultures.
See Table 1.
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Infiltrating Lymphocytes; (TGFβ): Transforming Growth Factor Beta.
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